NCT00001160 2026-04-14
Studies on Tumors of the Thyroid
National Institutes of Health Clinical Center (CC)
Recruiting
Clinical Trials
63 trialsNCT07529080 2026-04-14
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
University of Michigan Rogel Cancer Center
Phase NA Not yet recruiting
NCT02152995 2026-04-13
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03914300 2026-04-13
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04948437 2026-04-13
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT05463107 2026-04-13
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
National Taiwan University Hospital
Active not recruiting
NCT03753919 2026-03-11
DUTHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Terminated
NCT05575440 2026-02-27
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
Mayo Clinic
Recruiting
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT04544111 2025-10-07
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03690388 2025-09-25
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Exelixis
Phase 3 Active not recruiting
NCT02973997 2025-08-29
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Phase 2 Completed
NCT01723202 2025-08-24
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT06959641 2025-06-11
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
Phase 2 Recruiting
NCT05591092 2025-04-22
Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery
Mayo Clinic
Completed
NCT05410821 2025-04-01
Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Phase 1 Completed
NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT06437873 2024-05-31
Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC
Dezhou Hospital Qilu Hospital of Shandong University
Completed
NCT01398085 2024-05-08
IoN
University College, London
Phase 2/3 Active not recruiting
NCT00415233 2023-12-19
HiLo
University College, London
Phase 3 Unknown
NCT04031339 2023-05-10
ITCO
University of Roma La Sapienza
Unknown
NCT03506048 2022-11-10
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Emory University
Phase 2 Terminated
NCT00470496 2022-07-25
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT05052359 2021-10-01
Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours
National University Health System, Singapore
Completed
NCT01208051 2021-07-15
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01441154 2020-09-28
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
National Institutes of Health Clinical Center (CC)
Completed
NCT00668811 2020-08-05
IIT Sutent
Medstar Health Research Institute
Phase 2 Completed
NCT00104871 2018-12-19
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT03639662 2018-08-21
Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer
Assistance Publique Hopitaux De Marseille
Phase NA Unknown
NCT00416949 2018-07-18
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated
NCT01811212 2018-04-03
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026533 2017-06-06
Thalidomide in Treating Patients With Thyroid Cancer
University of Kentucky
Phase 2 Completed
NCT00095836 2017-05-31
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Massachusetts General Hospital
Phase 2 Completed
NCT00519896 2017-04-25
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Phase 2 Completed
NCT00937417 2017-04-24
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00729157 2017-03-15
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118248 2017-02-15
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01413113 2015-11-05
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
University of Washington
Phase 1 Completed
NCT00295763 2015-03-18
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
Sanofi
Phase 3 Completed
NCT01164176 2014-12-02
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Yonsei University
Phase 2 Completed
NCT00134043 2014-08-11
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098813 2014-05-28
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
National Cancer Institute (NCI)
Phase 2 Completed
NCT00061906 2014-02-11
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00098852 2014-01-06
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004062 2013-12-19
Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer
National Cancer Institute (NCI)
Phase 1 Completed